13th Oct 2020 16:07
(Alliance News) - Verici DX PLC on Tuesday announced its intention to admit to training on London's AIM market along with a fundraise.
The company develops clinical tests for organ transplant, which an understand how well a patient will or is responding to organ transplant - initially focus on kidney transplantation.
N+1 Singer is Verici's nominated adviser and sole bookrunner for the placing, restricted offer, and subscription - financial details of which have not been disclosed.
Renalytix AI PLC noted the announcement. In July, it proposed to distribute shares in Verici Dx Ltd - then a wholly owned subsidiary - with Renalytix shareholders becoming beneficial owners of their respective distribution shares.
Shares in Renalytix were down 1.1% at 440.00 pence in London on Tuesday.
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc